News

The transaction is valued at approximately $66 million in cash (subject to certain customary purchase price adjustments), $4 million in restricted Qiagen common stock and performance and development

Simultaneously, Gendux Molecular, an Introgen subsidiary, submitted a marketing authorization application to the European Medicines Evaluation Agency for the same indication. Advexin reportedly represents the first of a

According to the company, Zingo is an easy-to-administer, single-use, needle-free system that reduces the pain associated with peripheral intravenous line placements and blood draws in children three to

This orally administered small molecule is being developed primarily for inflammatory bowel disease (IBD). Treatment with GL1001 has decreased several disease activity measures in in vivo models of

On May 18, 2007, Taro and Sun Pharma’s subsidiaries entered into a merger agreement whereby Sun Pharma’s subsidiary would acquire Taro, which the Taro board of directors unanimously

Heidelberg will continue to be the company’s headquarters though Mr Silverman is based at the US subsidiary in Westborough, Massachusetts. Gerald Moller, chairman of mtm laboratories’ supervisory board,

The primary efficacy endpoint in this Phase II study was the change from baseline in the sputum Pseudomonas Aeruginosa colony forming units (CFU), an objective measure of the

The Phase II trial is designed as a randomized, double-blind, placebo-controlled, intent-to-treat, multicenter trial to evaluate the safety and efficacy of CPP-109 as a treatment for methamphetamine addiction.

The submission starts a 60-day period during which the FDA will examine the application for completeness. If the FDA accepts the inhaled formulation of treprostinil new drug application